Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry

Cangrelor, the first intravenous P2Y(12) inhibitor (P2Y(12)-I), has been approved on the basis of three large RCTs from the CHAMPION program which nevertheless have been criticized for the low bleeding risk of the enrolled patients, the large quote of chronic coronary syndromes, and the use of Clopi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pepe, Martino, Carulli, Eugenio, Larosa, Claudio, Napoli, Gianluigi, Nestola, Palma Luisa, Carella, Maria Cristina, Giordano, Salvatore, Tritto, Rocco, Bartolomucci, Francesco, Cirillo, Plinio, Zoccai, Giuseppe Biondi, Giordano, Arturo, Ciccone, Marco Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314899/
https://www.ncbi.nlm.nih.gov/pubmed/37393369
http://dx.doi.org/10.1038/s41598-023-37084-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314899/
https://www.ncbi.nlm.nih.gov/pubmed/37393369
http://dx.doi.org/10.1038/s41598-023-37084-2

Ejemplares similares